Here are the most recent publicly reported updates tying daraxonrasib to its RAS (KRAS) protein targets (i.e., its “RAS(ON)”/pan-RAS activity and how it’s being clinically positioned):
- May 10, 2026 — A report highlights daraxonrasib as a next-generation targeted approach for pancreatic cancer, framing it as an inhibitor meant to shut down growth signaling driven by mutated KRAS/RAS (“undruggable” class).[4]
- May 5, 2026 — A EurekAlert release reports initial anti-tumor activity for daraxonrasib from a Phase 1/2 trial in RAS-mutant pancreatic cancer, led by investigators at MD Anderson.[10]
- Apr 19, 2026 — Coverage discusses daraxonrasib in the context of new KRAS drug development, emphasizing attempts to improve outcomes compared with earlier KRAS inhibitor generations and resistance dynamics.[2]
- Jun 28, 2025 — OncLive reports the FDA Breakthrough Therapy Designation for daraxonrasib in KRAS G12X–mutant metastatic PDAC, reflecting regulatory recognition connected to clinical activity in a KRAS-mutant subgroup.[6]
- Jan 27, 2025 — OncLive reports clinical data suggesting daraxonrasib can show activity in RAS-mutated PDAC, with pharmacodynamic effects discussed via tumor DNA measures (ctDNA).[3]
- Aug 7, 2025 — A paper in PLOS ONE describes mechanism data in an osteosarcoma model, stating that daraxonrasib selectively attenuates signaling downstream of KRAS (including AKT/ETS1) in KRAS-mutant cells.[9]
What “protein target” means for daraxonrasib (in plain terms)
Recent reporting and mechanistic studies consistently describe daraxonrasib as a direct/tri-complex inhibitor designed to block oncogenic RAS signaling, with emphasis on KRAS (and broader “RAS(ON)” variant coverage) as the key oncogenic driver in cancers like PDAC.[4][9]
If you tell me which angle you care about—clinical trial results (PDAC/other tumors) vs molecular mechanism/biomarkers—I can narrow to just the most relevant latest items.
Sources
Revolution Medicines’ daraxonrasib shows promising clinical results for metastatic pancreatic cancer, targeting previously undruggable...
www.chemdiv.comA new drug targeting the KRAS mutation is transforming outcomes for pancreatic cancer patients, potentially opening doors for other cancers.
longevitytoday.comDaraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.
www.onclive.comNew research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and activate the immune system, offering the first targeted approach for patients with NRAS-mutant melanoma, an aggressive form of skin cancer with limited treatment options beyond immune checkpoint inhibitors. Results from the study were published in Cancer Immunology Research. It shows the potential for durable responses, laying the groundwork for future clinical trials and a...
www.eurekalert.orgKRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a ...
pmc.ncbi.nlm.nih.govTreatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.
www.onclive.comThe FDA has granted breakthrough therapy designation to daraxonrasib for metastatic pancreatic cancer with KRAS G12 mutations.
rarecancernews.comKRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a wide array of KRAS mutations and shows promise against pancreatic and lung cancers. However, the efficacy and mechanisms of action of daraxonrasib in osteosarcoma (OS) remain unclear. We evaluated the effects of daraxonrasib on the viability,...
journals.plos.orgThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.eurekalert.org